CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00169195
NCT00169195Phase 2Completed
CompareCT.gov

Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation

Lymphoma Study Association·interventional·Posted Sep 15, 2005·Updated Sep 2, 2015

In Brief

A Phase 2 clinical trial evaluating Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) for Diffuse Large Cell Lymphoma. Completed, enrolled 49 participants across 8 sites.

Detailed Summary

The Purpose of this study is to evaluate the efficacy and the safety of R-GEMOX in refractory/relapsed patients with CD20-positive large B-cell lymphoma who are not eligible for autologous transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large Cell Lymphoma
CountriesFrance
CollaboratorsHoffmann-La Roche, Sanofi-Synthelabo, Eli Lilly and Company

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartApr 1, 2003
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 20.8 years ago

Interventions

Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)drug